entertainment -WSS

entertainment

author：fashion 2025-10-02 08:57:29 - browse：8

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Lilly’s obesity pill cuts 15% of weight at highest dose in mid

hotspot

WSS

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Supreme Court rules employers must be more accommodating of religious observance

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Why the Crimean Bridge is key to Russia's war in Ukraine

Stanford president to resign after investigation of research

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

entertainment

entertainment

explore

Novavax promises a turnaround & Lilly roils the obesity market

ADA: All diabetes patients should be screened for liver condition

In Memoriam: Notable people who died in 2023

How dance can help health care workers heal from trauma

Activists slam private health insurers over coverage restrictions

Belarusian journalist sentenced to 4 years in prison as crackdown continues

United colonoscopy coverage change 'may cost lives,' doctors say

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Psychedelics group wrestles with new pharma identity

ADA: All diabetes patients should be screened for liver condition

Wikipedia

Man who had jail sentence commuted by Trump arrested again

Trump got a 'target letter.' What is one and what does it mean?

Medical experts are missing from AI regulatory conversations

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Why the Crimean Bridge is key to Russia's war in Ukraine

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

explore

hotspot

hotspot

leisure time